Q1 2026 EPS Estimates for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Cut by Analyst

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Stock analysts at Zacks Research reduced their Q1 2026 earnings estimates for Sarepta Therapeutics in a research note issued on Tuesday, April 23rd. Zacks Research analyst S. Ganoria now expects that the biotechnology company will post earnings per share of $2.01 for the quarter, down from their previous estimate of $2.09. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.13 per share.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.50. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The firm had revenue of $396.80 million for the quarter, compared to analysts’ expectations of $387.18 million. During the same quarter last year, the business earned ($1.24) earnings per share. The business’s revenue was up 53.6% on a year-over-year basis.

Other research analysts have also recently issued research reports about the stock. Wedbush restated an “outperform” rating and issued a $224.00 target price on shares of Sarepta Therapeutics in a report on Thursday, February 29th. Evercore ISI raised their price target on Sarepta Therapeutics from $108.00 to $138.00 and gave the stock an “in-line” rating in a research note on Tuesday, February 20th. BMO Capital Markets began coverage on Sarepta Therapeutics in a research note on Wednesday, January 31st. They issued an “outperform” rating and a $170.00 price target for the company. Citigroup raised their price target on Sarepta Therapeutics from $160.00 to $172.00 and gave the stock a “buy” rating in a research note on Thursday, February 29th. Finally, UBS Group raised their price objective on Sarepta Therapeutics from $164.00 to $167.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Four analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, Sarepta Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $158.38.

Sarepta Therapeutics Stock Up 0.1 %

Shares of Sarepta Therapeutics stock opened at $117.12 on Wednesday. The company has a debt-to-equity ratio of 1.32, a quick ratio of 3.45 and a current ratio of 3.95. Sarepta Therapeutics has a 52-week low of $55.25 and a 52-week high of $159.89. The stock has a market capitalization of $11.00 billion, a price-to-earnings ratio of -19.14 and a beta of 0.94. The company’s 50 day moving average price is $126.18 and its 200-day moving average price is $110.21.

Insider Transactions at Sarepta Therapeutics

In related news, Director Kathryn Jean Boor sold 761 shares of Sarepta Therapeutics stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $122.93, for a total value of $93,549.73. Following the completion of the sale, the director now directly owns 7,516 shares in the company, valued at approximately $923,941.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, insider Bilal Arif sold 2,000 shares of Sarepta Therapeutics stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $128.84, for a total value of $257,680.00. Following the completion of the sale, the insider now directly owns 26,836 shares in the company, valued at approximately $3,457,550.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Kathryn Jean Boor sold 761 shares of Sarepta Therapeutics stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $122.93, for a total value of $93,549.73. Following the completion of the sale, the director now owns 7,516 shares of the company’s stock, valued at $923,941.88. The disclosure for this sale can be found here. Insiders sold a total of 22,096 shares of company stock valued at $2,739,419 in the last quarter. 7.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Large investors have recently made changes to their positions in the company. Mather Group LLC. bought a new stake in shares of Sarepta Therapeutics during the 1st quarter valued at about $28,000. Montag A & Associates Inc. bought a new stake in shares of Sarepta Therapeutics during the 3rd quarter valued at about $30,000. Cary Street Partners Investment Advisory LLC grew its stake in shares of Sarepta Therapeutics by 154.0% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 154 shares during the period. Principal Securities Inc. bought a new stake in shares of Sarepta Therapeutics during the 4th quarter valued at about $26,000. Finally, GAMMA Investing LLC grew its stake in shares of Sarepta Therapeutics by 37.0% during the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 87 shares during the period. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.